H Sofen Selected Research

Janus Kinase Inhibitors

2/2017	Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
1/2015	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

H Sofen Research Topics

Disease

13	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2021 - 12/2013
1	Atopic Dermatitis (Atopic Eczema) 10/2019
1	Eczema 10/2019
1	Inflammation (Inflammations) 10/2019
1	Pruritus (Itching) 10/2019
1	Atherosclerosis 10/2019
1	Psoriatic Arthritis 10/2017
1	Angioedema 06/2017
1	Urticaria (Hives) 06/2017
1	Nail Diseases (Nail Disease) 02/2014
1	Melanoma (Melanoma, Malignant) 04/2011

Drug/Important Bio-Agent (IBA)

3	Monoclonal AntibodiesIBA 12/2019 - 02/2015
3	ixekizumabIBA 01/2018 - 06/2017
3	Ustekinumab (CNTO 1275)FDA Link 10/2017 - 12/2013
2	tildrakizumabIBA 12/2019 - 10/2019
2	Biomarkers (Surrogate Marker)IBA 10/2019 - 04/2011
2	secukinumabIBA 10/2017 - 02/2015
2	tofacitinibIBA 02/2017 - 01/2015
2	Janus Kinase InhibitorsIBA 02/2017 - 01/2015
2	Prostaglandins AIBA 01/2015 - 02/2014
1	Certolizumab Pegol FDA Link 12/2021
1	apremilastIBA 10/2021
1	Janus KinasesIBA 10/2019
1	gusacitinibIBA 10/2019
1	Syk KinaseIBA 10/2019
1	E-SelectinIBA 10/2019
1	Etanercept (Enbrel)FDA Link 11/2017
1	Interleukin-17 (Interleukin 17)IBA 10/2017
1	Omalizumab (Xolair)FDA Link 06/2017
1	Immunoglobulin A (IgA)IBA 02/2015

Therapy/Procedure

2	Retreatment 02/2017 - 01/2015
1	Therapeutics 06/2017
1	Subcutaneous Injections 02/2015